Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Operating Margin
Biocytogen Pharmaceuticals Beijing Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
CN |
B
|
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
|
4.9B HKD |
15%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
329.3B USD |
29%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
155.5B USD |
22%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
131.5B USD |
38%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.9B USD |
40%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
119.6B AUD |
26%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
62.8B USD |
30%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
NL |
![]() |
argenx SE
XBRU:ARGX
|
29.8B EUR |
-1%
|
Biocytogen Pharmaceuticals Beijing Co Ltd
Glance View
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-09-01. The firm operates two business segments. The Drug Development Business segment is mainly engaged in the research and development of oncology and autoimmune disease treatments, as well as antibody development. The Preclinical Research Service segment is mainly engaged in gene editing, preclinical pharmacological efficacy evaluation and model animal sales.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Biocytogen Pharmaceuticals Beijing Co Ltd's most recent financial statements, the company has Operating Margin of 15.4%.